Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel
OTCMKTS:GTHP

Guided Therapeutics Q1 2025 Earnings Report

Guided Therapeutics logo
$0.29 0.00 (0.00%)
As of 08/4/2026
ProfileEarnings History

Guided Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Guided Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Guided Therapeutics Announcement Details

Quarter
Q1 2025
Date
5/15/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Guided Therapeutics Earnings Headlines

Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor
July 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/guided-therapeutics-receives-80-000-130000603.html
Guided Therapeutics Announces New Agreement with Distribution Partner Yuanshuo Medical Instruments Corporation
July 14, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/guided-therapeutics-announces-agreement-distribution-130000412.html
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA
June 16, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260616805816/en/guided-therapeutics-files-premarket-approval-application-clinical-report-with-fda/
Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
March 31, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/guided-therapeutics-provides-updates-fda-130000041.html
Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
December 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/analysis-guided-therapeutics-fda-study-140000495.html
See More Guided Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Guided Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guided Therapeutics and other key companies, straight to your email.

About Guided Therapeutics

Guided Therapeutics (OTCMKTS:GTHP), Inc. is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S. Food and Drug Administration in 2013 and obtained CE marking for distribution within the European Union, enabling it to market its technology across multiple regions. Guided Therapeutics collaborates with academic and research institutions—including the National Cancer Institute—to validate its imaging algorithms through clinical studies conducted in both the United States and Europe. These partnerships have informed ongoing refinements to the LuViva platform and supported expansion of its distribution channels via direct sales and strategic alliances.

Founded in 1993 and headquartered in Melbourne, Florida, Guided Therapeutics leverages a multidisciplinary management team with expertise in biomedical engineering, oncology, and regulatory affairs. Building on the core technology behind LuViva, the company is exploring additional applications in gynecologic and dermatologic diagnostics. Its long-term strategy aims to extend its non‐invasive optical imaging capabilities to address a broader range of clinical needs in early disease detection.

View Guided Therapeutics Profile
Earnings Tools